India is among the first few countries in the world and the third Asian market after the UAE and Japan where Eli Lilly & Co.‘s Trulicity (dulaglutide) has been rolled out and the glucagon-like peptide-1 (GLP-1) receptor agonist has been priced at INR2,499 ($38) for a week, translating into an annual cost of around INR129,948.
By contrast, the annual cost in the UK of dulaglutide 1.5mg or 0.75mg once weekly is £1,182.35 ($1,709), as per details in NICE's evidence summary for the product in June...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?